Protea Biosciences 10-Q 12 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 11, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	Protea Biosciences Group, Inc.
Entity Central Index Key	1,335,103
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	PRGB
Entity Common Stock, Shares Outstanding		114,991,718

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 121,366	$ 322,877
Trade accounts receivable, net	297,938	273,914
Other receivables	0	119,230
Inventory	56,495	161,301
Prepaid expenses	205,745	54,022
Total current assets	681,544	931,344
Property and equipment, net	3,042,488	2,960,090
Other noncurrent assets	105,248	136,693
Total Assets	3,829,280	4,028,127
Current Liabilities:
Current maturities on short and long-term debt, net of discount	2,716,926	1,457,800
Accounts payable	1,272,780	1,253,385
Bank line of credit	3,000,000	3,000,000
Loans payable to stockholders, net of discount	2,135,000	1,381,498
Derivative liabilities	75,794	154,058
Other payables and accrued expenses	498,801	518,821
Total current liabilities	9,699,301	7,765,562
Long-term debt - net of current portion	2,125,261	1,817,237
Stockholders' Equity:
Preferred stock ($.0001 par value; 10,000,000 shares authorized; none and 3,337,725 issued or outstanding at June 30 , 2015 and December 31, 2014)	0	334
Common stock ($.0001 par value; 250,000,000 shares authorized; 114,900,808 and 66,588,600 shares issued and outstanding at June 30, 2015 and December 31, 2014)	11,490	6,659
Additional paid in capital	67,288,833	64,305,743
Accumulated deficit	(75,295,580)	(69,867,118)
Accumulated other comprehensive (loss) income	(25)	(290)
Total Stockholders' Equity (Deficit)	(7,995,282)	(5,554,672)
Total Liabilities and Stockholders' Equity	$ 3,829,280	$ 4,028,127

Consolidated Balance Sheets _Pa

Consolidated Balance Sheets [Parenthetical] - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	3,337,725
Preferred Stock, Shares Outstanding	0	3,337,725
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	114,900,808	66,588,600
Common stock, shares outstanding	114,900,808	66,588,600

Consolidated Statements of Oper

Consolidated Statements of Operations and Total Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Gross revenue	$ 511,783	$ 346,561	$ 920,656	$ 814,661
Cost of revenue	(166,403)	(180,234)	(306,191)	(410,970)
Gross profit	345,380	166,327	614,465	403,691
Selling, general, administrative expenses	(1,778,048)	(2,565,856)	(3,790,569)	(4,688,561)
Research and development expense	(369,901)	(804,030)	(770,994)	(1,525,983)
Loss from operations	(1,802,569)	(3,203,559)	(3,947,098)	(5,810,853)
Other income (expense):
Interest and exchange income (expense)	4,462	(133)	6,003	32
Interest expense	(326,891)	(206,317)	(490,941)	(372,480)
Debt conversion inducement cost	0	0	(60,419)	0
Gain (loss) on asset disposal	57,104	6,000	56,231	(18,768)
Change in fair value of derivative	(237,014)	(42,329)	(836,182)	23,593
Total other income (expense)	(502,339)	(242,779)	(1,325,308)	(367,623)
Loss before income taxes	(2,304,908)	(3,446,338)	(5,272,406)	(6,178,476)
Income taxes	0	0	0	0
Net loss	(2,304,908)	(3,446,338)	(5,272,406)	(6,178,476)
Foreign currency translation adjustment	657	(14,304)	265	(13,535)
Total comprehensive loss	$ (2,304,251)	$ (3,460,642)	$ (5,272,141)	$ (6,192,011)
Net loss per share - basic and diluted (in dollars per share)	$ (0.02)	$ (0.05)	$ (0.05)	$ (0.09)
Weighted average number of shares outstanding - basic and diluted (in shares)	106,157,191	65,655,378	100,243,815	65,556,136

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - 6 months ended Jun. 30, 2015 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2014	$ (5,554,672)	$ 334	$ 6,659	$ 64,305,743	$ (69,867,118)	$ (290)
Balance (in shares) at Dec. 31, 2014		3,337,725	66,588,600
Issuance of preferred stock, net issuance costs	361,962	$ 37	$ 0	361,925	0	0
Issuance of preferred stock, net issuance costs (in shares)		370,050	0
Stock dividend declared on preferred stock	0	$ 8	$ 0	156,048	(156,056)
Stock dividend declared on preferred stock (Shares)		78,040	0
Issuance of stock upon conversion of convertible debentures	550,261	$ 0	$ 220	550,041	0	0
Issuance of stock upon conversion of convertible debentures (in shares)		0	2,201,046
Issuance of stock for services	93,000		$ 30	92,970
Issuance of stock for services (in shares)			300,000
Issuance of stock under anti-dilution provision	945,451	$ 0	$ 1,552	943,899	0	0
Issuance of stock under anti-dilution provision (in shares)		0	15,524,642
Conversion of preferred stock to common stock	0	$ (379)	$ 3,029	(2,650)	0	0
Conversion of preferred stock to common stock (Shares)		(3,785,815)	30,286,520
Stock-based compensation expense	159,154	$ 0	$ 0	159,154	0	0
Stock warrants issued for services and debt	515,923	0	0	515,923	0	0
Stock warrants issued as part of debt conversion inducement cost	60,419			60,419
Stock warrants issued to placement agent	170,418	0	0	170,418	0	0
Recognition of derivative liability	(25,057)	0	0	(25,057)	0	0
Net loss	(5,272,406)	0	0	0	(5,272,406)	0
Foreign currency translation adjustment	265	0	0	0	0	265
Balance at Jun. 30, 2015	$ (7,995,282)	$ 0	$ 11,490	$ 67,288,833	$ (75,295,580)	$ (25)
Balance (in shares) at Jun. 30, 2015		0	114,900,808

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Equity (Deficit) [Parenthetical]	6 Months Ended
	Jun. 30, 2015USD ($)
Preferred Stock [Member]
Payments of Stock Issuance Costs	$ 378,138

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (5,272,406)	$ (6,178,476)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	356,055	430,771
Non-cash compensation	159,154	179,049
Issuance of common stock and warrants for services	191,683	515,463
Issuance of preferred and common stock for accrued interest	192,785	0
Accretion of discount on short-term convertible debenture	107,527	0
Accretion of convertible debenture discount	117,041	125,645
Debt conversion inducement cost	60,419	0
Capitalized interest on debt modification	34,596	0
(Gain) Loss on disposal of fixed assets	(56,231)	18,768
Bad debt expense	119,230	1,200
Loss (gain) from change in fair value of derivative	836,182	(23,593)
Net change in assets: Decrease (increase)
Trade accounts receivable	(24,024)	132,359
Prepaid expenses	(151,723)	226,049
Other receivables	0	7,452
Inventory	149,379	(40,215)
Other noncurrent assets	(93,014)	152
Net change in liabilities: Increase (decrease)
Trade accounts payable	35,787	1,596,754
Other payables and accrued expenses	(20,020)	(279,128)
Net cash used in operating activities	(3,257,580)	(3,287,750)
Cash flows from investing activities:
Purchase of and deposits on equipment	(44,132)	(119,983)
Proceeds from sale of equipment	134,169	6,000
Proceeds from subsidiary sale - Option Fee	0	600,000
Net cash provided by investing activities	90,037	486,017
Cash flows from financing activities:
Net advances on bank line of credit	0	275,000
Proceeds from sale of preferred stock, net	538,327	0
Proceeds from sale of common stock, net	0	(12,500)
Proceeds from short and long-term debt, net	1,690,656	283,500
Proceeds from shareholder debt	1,048,000	2,025,000
Repayment of shareholder, short and long-term debt	(311,216)	(325,890)
Repayment of Obligation related to the Letter of Credit	0	(238,695)
Net cash provided by financing activities	2,965,767	2,006,415
Effect of exchange rate changes on cash	265	(13,535)
Net (decrease) in cash	(201,511)	(808,853)
Cash, beginning of period	322,877	1,086,330
Cash, end of period	121,366	277,477
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	124,294	136,101
Supplemental disclosure of non-cash investing and financing activities:
Financed equipment	516,832	629,476
Debt converted to common stock	550,260	0
Dividends paid in preferred stock	156,056	0
Stock warrants issued to placement agent	$ 170,418	$ 0

Description of Company and Natu

Description of Company and Nature of Business	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Description of Company and Nature of Business Protea Biosciences Group, Inc. (referred to as “Protea”, “the Company”, “we”, “us” and “our”) is an emerging growth, molecular information company providing innovative bioanalytical technologies and capabilities to the pharmaceutical, diagnostic and life science industries. “Molecular information” refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company’s technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the products of all living cells and life forms. The Company is applying its technology to the development of next generation “direct molecular imaging” technology and service capabilities that support pharmaceutical and life science research, and enable more rapid and comprehensive molecular profiling of human disease.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company’s 10-K for the year ended December 31, 2014. The Company’s financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has funded its activities to date almost exclusively from debt and equity financings. The Company will continue to require substantial funds to advance the research and development of its core technologies and to develop new products and services based upon its proprietary protein recovery and identification technologies. Management intends to meet its operating cash flow requirements primarily from the sale of equity and debt securities. The Company seeks additional capital through sales of equity securities or convertible debt and, if appropriate, to pursue partnerships to advance various research and development activities. The Company may also consider the sale of certain assets, or entering into a transaction such as a merger with a business complimentary to theirs. While the Company believes that it will be successful in obtaining the necessary financing to fund its operations, they have no committed sources of funding and are not assured that additional funding will be available to them. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The Company follows the provisions of FASB ASC 605, “Revenue Recognition.” We recognize revenue of products when persuasive evidence of a sale arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred/title has passed, and collectability of the sales price is reasonably assured. The Company recognizes revenue from the sale of its ProteaPlot™ software when bundled with the LAESI platform, which facilitates operating the instrument and storage and display of datasets. The Company also recognizes revenue of standalone sales of ProteaPlot™, which generally consists of additional user licenses. The Company accounts for shipping and handling costs in accordance with the provisions of FASB ASC 605-45-45, “Revenue Recognition – Principal Agent Considerations,” which requires all amounts charged to customers for shipping and handling to be classified as revenues. Shipping and handling costs charged to customers are recorded in the period the related product sales revenue is recognized. Regarding short-term service contracts, the majority of these service contracts involve the processing of imaging and bioanalytical samples for pharmaceutical and academic/clinical research laboratories. These contracts generally provide for a fixed fee for each method developed or sample processed and revenue is recognized when the analysis is complete and a report is delivered. For longer-term contracts involving multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. We perform this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) have standalone value to the customer and (ii) the delivery or performance of the service(s) is probable and substantially in our control. Revenue on multiple revenue arrangements is recognized using a proportional method for each separately identified element. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or, if there is no predominant deliverable, upon delivery of the final element of the arrangement. Revenues from grants are based upon internal costs that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by the Company that is related to the grants. The Company has revenue from four major components: molecular information services, LAESI instrument platform, research products, and grants and other collaboration revenues. Three Months Ended Six Months Ended June 30, 2015 June 30, 2014 June 30, 2015 June 30, 2014 Molecular Information Services $ 219,064 $ 59,375 $ 389,708 $ 229,945 LAESI Instrument Platform 152,625 140,500 305,987 318,500 Research Products 86,387 120,361 152,910 215,703 Grants and Other Collaborations 53,707 26,325 72,051 50,513 Gross Revenue $ 511,783 $ 346,561 $ 920,656 $ 814,661 The Company’s 33 20 50 The Company determined the fair market value of the investment as having no value as AzurRx is still in early stages of organizing, has not reached commercialization, and will continue realizing substantial research and development expenses. In addition, the Company has suspended the equity method of accounting, as the losses have reduced the Company’s basis in AzurRx below zero. The value of this investment as presented on our consolidated balance sheet was $ 0 June 30, 2015 December 31, 2014 Other receivables $ - $ 119,230 Other receivables – current $ - $ 119,230 Deposits $ 105,248 $ 136,693 Other assets – noncurrent $ 105,248 $ 136,693 June 30, 2015 December 31, 2014 Accrued expenses $ 56,564 $ 31,104 Accrued interest 98,424 201,844 Accrued warranties 50,000 50,000 Accrued payroll and benefits 233,055 219,973 Unearned revenue 60,758 15,900 Other payables and accrued expenses $ 498,801 $ 518,821 The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks; however, the Company has certain financial instruments that are embedded derivatives associated with capital raises and common stock purchase warrants. The Company evaluates all of its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 815-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity. We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities. Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable. Level 3 – inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of common stock warrants). The Company has entered into certain financial instruments and contracts such as equity financing arrangements for the issuance of common stock, which include anti-dilution arrangements “Down Round Protection” and detachable stock warrants that are i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are recorded as derivative liabilities at fair value at the issuance date. Subsequent changes in fair value are recorded through the Statement of Comprehensive Loss. For the Company, the Level 3 financial liability is the derivative liability related to the common stock and warrants that include “Down Round Protection” and they were valued using the “Monte Carlo Simulation” technique. This technique, while the majority of inputs are Level 2, necessarily incorporates a Capital Raise Assumption which is unobservable and, therefore, a Level 3 input. June 30, 2015 Expected Life (Years) Risk Free Rate Volatility Probability of a Capital Raise Derivative liabilities 2.37-3.83 1.01 % 74.57 % 100 % Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company’s derivative liabilities are related to common stock issuances, detachable warrants issued in conjunction with debt and common stock, or warrants issued to the placement agents for financial instrument issuances. Fair Value Measurements at June 30, 2015 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities – common stock - - - - Derivative liabilities – warrants 75,794 - - 75,794 Total $ 75,794 - - $ 75,794 For the quarter ended June 30, 2015, the Company modified its assessment of the probability of future down-rounds, due to a high probability of closing on a subsequent capital raises at levels that would not result in anti-dilution triggers, currently at $ 0.25 Fair Value Measurements at December 31, 2014 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities – common stock $ 88,871 - - $ 88,871 Derivative liabilities – warrants 65,187 - - 65,187 Total $ 154,058 - - $ 154,058 As a result of the 2014 winter offering, the Company issued 15,524,642 10,122,067 1,771,362 5,402,575 945,451 Six Months Ended June 30, 2015 Derivative Liabilities - Common Stock Derivative Total Fair Value Measurements Using Level 3 Balance at January 1, 2015 $ 88,871 $ 65,187 $ 154,058 Issuance of warrants - 5,948 5,948 Anti-dilution shares issued (945,451) (945,451) Unrealized loss on derivative liabilities 856,580 (20,398) 836,182 Recognition of derivative liabilities - 25,057 25,057 Balance at June 30, 2015 $ - $ 75,794 $ 75,794 Year Ended December 31, 2014 Derivative Liabilities - Common Stock Derivative Total Fair Value Measurements Using Level 3 Beginning balance at January 1, 2014 $ 558,799 $ 64,788 $ 623,587 Issuance of warrants - 2,550 2,550 Anti-dilution shares to be issued (1,771,362) - (1,771,362) Unrealized (gain) loss on derivative liabilities 1,301,434 (11,449) 1,289,985 Recognition of derivative liabilities - 9,298 9,298 Balance at December 31, 2014 $ 88,871 $ 65,187 $ 154,058 Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Common share equivalents (which may consist of options, warrants and convertible debt) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 79,823,000 84,834,000 In May 2014, the FASB issued a standard on revenue recognition that provides a single, comprehensive revenue recognition model for all contracts with customers. The standard is principle-based and provides a five-step model to determine the measurement of revenue and timing of when it is recognized. The core principle is that a company will recognize revenue to reflect the transfer of goods or services to customers at an amount that the company expects to be entitled to in exchange for those goods or services. This standard is to be applied retrospectively and is effective for fiscal years beginning after December 15, 2017 as deferred by the FASB in July 2015. The Company is evaluating the impact that this standard will have on its consolidated financial statements. In June 2014, the FASB issued authoritative guidance on stock compensation, which requires performance targets that affect vesting and can be achieved after the requisite service period, to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If achievement of the performance target becomes probable before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The amendments are effective for fiscal years beginning after December 15, 2015. The Company is evaluating the impact that this standard will have on its consolidated financial statements. In August 2014, the FASB issued authoritative guidance on going concern disclosures and financial statement presentation, which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). This standard provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the financial statement footnotes. This standard is effective for annual reporting periods ending after December 15, 2016, and to annual and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements and related disclosures. In November, 2014, the FASB issued ASU 2014-16, "Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force)." The ASU clarifies how current guidance should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of a host contract. The ASU is effective for fiscal years and interim periods beginning after December 15, 2015. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements. In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs”. This standard update requires an entity to present debt issuance costs on the balance sheet as a direct deduction from the related debt liability as opposed to an asset. Amortization of the costs will continue to be reported as interest expense. The update is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued, and the new guidance would be applied retrospectively to all prior periods presented. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements and related disclosures. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory”. This standard requires that inventory be valued at the lower of cost or net realizable value, which is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update is effective for fiscal years beginning after December 14, 2016, including interim periods within those fiscal years. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	3. Inventory Inventory represents finished goods and work in progress. Inventory: June 30, 2015 December 31, 2014 Finished goods $ 14,992 $ 18,739 Work in progress 41,503 142,562 Total Inventory $ 56,495 $ 161,301

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment Equipment 5 - 10 years Vehicle 5 years Leasehold improvements Life of lease Software 3 years June 30, 2015 December 31, 2014 Lab equipment $ 7,011,067 $ 7,313,979 Computer equipment 540,212 540,814 Office equipment 191,248 229,785 Leasehold improvements 443,639 434,304 8,186,166 8,518,882 Accumulated depreciation (5,143,678) (5,558,792) Property and equipment, net $ 3,042,488 $ 2,960,090 For the three months and six months ended June 30, 2015, depreciation expense was $ 181,084 356,055 224,455 430,528

Bank Line of Credit

Bank Line of Credit	6 Months Ended
	Jun. 30, 2015
Bank Line of Credit [Abstract]
Bank Line of Credit [Text Block]	5. Bank Line of Credit A subsidiary of the Company has a line of credit that is authorized to $ 3,000,000 3,000,000 5.87

Loans Payable to Stockholders

Loans Payable to Stockholders	6 Months Ended
	Jun. 30, 2015
Loan Payable [Abstract]
Loans Payable to Stockholders [Text Block]	6. Loans Payable to Stockholders On August 6, 2013, the Company entered into a Note and Warrant Purchase Agreement (the “Summit Agreement”) with Summit Resources, Inc. (“Summit”), an affiliate of Steve Antoline, a director of the Company, pursuant to which Summit acquired (a) a promissory note (the “Summit Note”) bearing simple interest at a rate of 10 600,000 1,000,000 1.10 134,117 150,000 423,915 94,757 176,085 87,707 1,055,165 0.25 527,583 0.50 39,360 28,964 During 2014, the Company received advances equal to an aggregate of $ 1,415,000 10 1,415,000 1,415,000 0.80 1,500,000 900,000 101,177 250,000 10,950 1,074,773 165,000 105,078 1,080,312 0.25 540,156 0.50 7,227 31,455 1,000,000 917,000 During 2014, the Company received advances equal to an aggregate of $ 540,000 370,000 During 2015, the Company received advances equal to an aggregate of $ 1,048,000

Short and Long-term Debt

Short and Long-term Debt	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	7. Short and Long-term Debt 1) Note Payable to the West Virginia Development Office (“WVDO”) In March 2007, the Company obtained an 8-year loan in the amount of $685,000 from the WVDO. The note bears interest at 3% providing for 96 monthly principal and interest payments of $8,035 through April 2015, at which time the note was due and payable. The note was secured by equipment costing $1,057,167. On February 4, 2015, the repayment terms were modified, whereby the WVDO approved a deferral of principal and interest until December 31, 2015 with the final payment due January 2017. 2) Note Payable to the West Virginia Economic Development Authority (“WVEDA”) In August 2009, the Company obtained a 10-year loan in the amount of $242,631 from the WVEDA. The note bears interest at 4% providing for 120 monthly principal and interest payments of $2,457 through August 2019, at which time the note was due and payable. The note was secured by 50% of equipment costing $531,522. As of March 31, 2015, the Company was in arrears on the note. Effective May 1, 2015, the Company and WVEDA entered into the First Amendment to Promissory Note; whereby, the original note was modified so that the remaining principal balance is payable in five annual installments; the next payment of $33,880 will be due on December 31, 2015 with final payment due August 3, 2019. If the Company fails to make any of the five remaining payments, the WVEDA shall increase the interest rate by 1.5% on each successive payment failure with all principal and unpaid interest due on August 3, 2019. 3) Note Payable to the West Virginia Infrastructure and Jobs Development Council (“WVIJDC”) In August 2009, the Company obtained a 10-year loan in the amount of $242,630 from the WVIJDC. The note bears interest at 3.25% providing for 120 monthly principal and interest payments of $2,371 through August 2019, at which time the note was due and payable. The note was secured by 50% of equipment costing $531,522. On February 4, 2015, the repayment terms were modified, whereby the WVIJDC approved a deferral of principal and interest until December 31, 2015 with final payment due April 2021. 4) Note Payable to the West Virginia Economic Development Authority (“WVEDA”) In October 2010, the Company issued a 10-year note in the amount of $900,000 from the WVEDA. The note bears interest at 3.26% providing for 120 monthly principal and interest payments of $8,802 through October 2020, at which time the note was due and payable. The note was secured by equipment costing $477,095. As of March 31, 2015, the Company was in arrears on the note. Effective May 1, 2015, the Company and WVEDA entered into the First Amendment to Promissory Note; whereby, the original note was modified so that the remaining principal balance is payable in six annual installments; the next payment of $125,990 will be due on December 31, 2015 with final payment due October 21, 2020. If the Company fails to make any of the remaining payments, the WVEDA shall increase the interest rate by 1.5% on each successive payment failure with all principal and unpaid interest due on October 21, 2020. 5) Note Payable to the West Virginia Infrastructure and Jobs Development Council (“WVIJDC”) In December 2010, the Company issued a 10-year note in the amount of $900,000 from the WVIJDC. The note bears interest at 3.25% providing for 120 monthly principal and interest payments of $8,781 through December 2020, at which time the note was due and payable. The note was secured by equipment costing $1,098,249. On February 4, 2015, the repayment terms were modified, whereby the WVIJDC approved a deferral of principal and interest until December 31, 2015 with final payment due August 2022. 6) Convertible Promissory Note Payable to the West Virginia Jobs Investment Trust Board (“WVJITB”) In March 2012, the Company issued an 18-month note in the amount of $290,000 from the WVJITB. The note bears interest at 6% providing for monthly interest-only payments starting April 2012 through August 2013, then final interest and principal payments due September 2013. The note has an adjustable conversion price, initially $2.00 per share, and includes a stock warrant for 72,500 shares (see Note 9, Stock Warrants). On December 13, 2013, the Company and the WVJITB entered into a Loan Modification Agreement whereby the maturity date changed from September 14, 2013 to $100,000 due on March 15, 2014 and the remaining $190,000 due on June 15, 2014. The WVJITB and the Company signed three addendums to the note extending the maturity date and deferring interest and principal payments until March 2, 2015. During 2014, the Company made interest only payments through October 31, 2014. On February 2, 2015, the Company and WVJITB entered into a Loan Modification Agreement whereby the interest payable for the periods of October 31, 2014 through June 30, 2015 would be due on June 30, 2015. The maturity date of the loan was also modified and extended to December 31, 2015. 7) Convertible Promissory Note Payable to the West Virginia Jobs Investment Trust Board (“WVJITB”) In April 2012, the Company issued a 3-month note in the amount of $400,000 from the WVJITB. The note bears interest at 10% providing for monthly interest-only payments starting May 2012 through June 2012, then final interest and principal payments due July 2012. The note includes a stock warrant for 88,889 shares (see Note 9, Stock Warrants). The WVJITB and the Company have signed several addendums to the note extending the maturity date and reducing the price of converting into common shares to $0.50 per share. The WVJITB further extended the maturity date until November 29, 2013, with a $100,000 principal payment due on or before November 15, 2013. The Company repaid the $100,000 as agreed, which reduced the principal outstanding balance to $300,000. The WVJITB and the Company signed four addendums to the note extending the maturity date and deferring interest and principal payments until March 2, 2015. During 2014, the Company made interest only payments through October 31, 2014. On February 2, 2015, the Company and WVJITB entered into a Loan Modification Agreement whereby the interest payable for the periods of October 31, 2014 through June 30, 2015 would be due on June 30, 2015. The maturity date of the loan was also modified and extended to December 31, 2015. 8) Convertible Promissory Note Payable to the West Virginia High Technology Consortium Foundation (“WVHTCF”) In May 2012, the Company issued a 30-month note in the amount of $200,000 from the WVHTCF. The note bears interest at 8% providing for 25 monthly principal and interest payments of $9,001 starting December 2012 through November 2014, then final interest and principal payments due December 2014. The note was secured by 50% of equipment costing $447,320. On April 1, 2015, the Company and WVHTCF entered into the First Amendment to Promissory Note whereby the original note was modified so that principal balance of $74,726.08 is payable in nine monthly installments; the next payment of $8,789.37 will be due on April 15, 2015 with final payment due December 15, 2015. As of June 30, 2015, the Company is current on the note. 9) Note Payable to the West Virginia Economic Development Authority (“WVEDA”) In June 2012, the Company issued a 10-year note in the amount of $200,000 from the WVEDA. The note bears interest at 2% providing for 120 monthly principal and interest payments of $1,840 through June 2022, at which time the note was due and payable. The note was secured by 50% of equipment costing $447,320. As of March 31, 2015, the Company was in arrears on the note. On May 1, 2015, the Company and WVEDA entered into the First Amendment to Promissory Note; whereby, the original note was modified so that the remaining principal balance is payable in eight annual installments; the next payment of $26,673 will be due on December 31, 2015 with final payment due June 11, 2022. If the Company fails to make any of remaining payments, the WVEDA shall increase the interest rate by 1.5% on each successive payment failure with all principal and unpaid interest due on June 11, 2022. 10) Short-term Convertible Debenture In May 2015, the Company received an aggregate of $2,000,000 in gross cash proceeds, less transaction costs such as commission and legal fees of $309,344, from one accredited investor in connection with the sale of a 20% original issue discount unsecured convertible debenture (the “Debenture”) due November 22, 2015, pursuant to the terms and condition of a Subscription Agreement. The Company issued (a) the Debenture with a principal amount of $2,500,000 that bears interest at a rate of 10% per annum, and (b) a three-year warrant to purchase up to 7,500,000 shares of common stock of the Company par value $0.001 per share at an exercise price of $0.325 per share. The Debenture may be converted in whole or in part, into shares of Common Stock at a conversion price of $0.25 per share. The relative fair value of these warrants was estimated to be $411,750, which was recorded as a discount to the promissory note, and will be accreted over the life of the loan. The Company recognized accretion expense of $68,625 related to the fair value of the warrants and interest expense of $107,527 related to the original issue discount during the six months ended June 30, 2015. As of June 30, 2015, the outstanding balance was $2,500,000 or $1,455,058, net of discount. 11) Capital Leases From time to time, in the normal course of business, the Company enters into capital leases to finance equipment. As of June 30, 2015, the Company had five capital lease obligations outstanding with imputed interest rates ranging from 5.86% to 6.00%. The leases require 24-60 monthly payments and begin to expire in December 2016 through October 2019. These leases are secured by equipment with an aggregate cost of $1,580,257. As of June 30, 2015, the Company was current on all lease payments. Total debts outstanding are as follows: June 30, 2015 December 31, 2014 1) Note Payable to the WVDO $ 100,656 $ 99,365 2) Note Payable to the WVEDA 143,312 141,369 3) Note Payable to the WVIJDC 139,229 139,128 4) Note Payable to the WVEDA 572,148 617,767 5) Note Payable to the WVIJDC 581,987 630,738 6) Note Payable to the WVJITB 290,000 290,000 7) Note Payable to the WVJITB 300,000 300,000 8) Note Payable to the WVHTCF 47,863 69,888 9) Note Payable to the WVEDA 168,362 166,258 10) Convertible Debentures 2,500,000 - 11) Capital leases 1,043,572 820,524 Total 5,887,129 3,275,037 Less: current portion (2,716,926 ) (1,457,800 ) Less: unamortized discount (735,598 ) - Less: transaction costs (309,344 ) - Long-term portion $ 2,125,261 $ 1,817,237 Future required minimum principal repayments over the next five years are as follows: Year Ending December 31: Future Required 2015 $ 3,444,045 2016 739,424 2017 556,334 2018 371,822 2019 & Thereafter 775,504 Total $ 5,887,129

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Common Stock [Text Block]	8. Common Stock The Company is authorized to issue a total of 260,000,000 250,000,000 10,000,000 Common Stock .0001 # Shares Par Price Gross Value of Services Obtained Par Additional Paid in Capital (1) Balance at December 31, 2014 66,588,600 $ .0001 Various $ 53,708,521 $ 1,814,673 $ 6,659 $ 55,516,535 Issuance of stock (2) 2,201,046 .0001 $ 0.25 550,261 - 220 550,041 Issuance of stock (3) 30,286,520 .0001 $ 0.25 - - 3,029 (2,650) Issuance of stock (4) 15,524,642 .0001 $ 0.25 - - 1,552 (1,552) Issuance of stock (5) 300,000 .0001 $ 0.31 - $ 93,000 30 92,970 Balance at June 30, 2015 114,900,808 $ 54,258,782 $ 1,907,673 $ 11,490 $ 56,155,344 (1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options. (2) Shares issued for conversion of an aggregate of $ 341,085 192,785 16,391 (3) Shares issued upon conversion of preferred stock and accrued dividends thereon and contained an anti-dilution provision. (4) Shares issued under certain anti-dilution privileges. (5) Shares issued to a consultant for services rendered. Shares do not contain anti-dilution provision. The Company issued 15,524,642 shares of Common Stock to investors in the Company’s winter 2013 private placement of Common Stock and Common Stock warrants pursuant to anti-dilution rights.

Preferred Stock

Preferred Stock	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Preferred Stock [Text Block]	9. Preferred Stock Preferred Stock # Shares Par Price Gross Par Additional Paid in Capital (1) Balance at December 31, 2014 3,337,725 $ .0001 $ 2.00 $ 6,675,452 $ 334 $ 6,675,118 Issuance of stock (2) 370,050 .0001 $ 2.00 740,100 37 740,063 Stock dividend 78,040 .0001 $ 2.00 (156,056) 8 156,048 Conversion of preferred stock (3,785,815) .0001 $ 2.00 (7,259,496) (379) (7,571,229) Balance at June 30, 2015 - $ - $ - $ - (1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options. (2) Shares issued contain an anti-dilution provision expiring upon the conversion to common stock. During 2014 and 2015, the Company sold units of preferred stock each consisting of 50,000 3 200,000 0.375 2.00 The Preferred Stock automatically converted into shares of Common Stock determined by dividing the stated value by $0.25 per share on March 31, 2015. 6.0

Stock Options and Stock-based C

Stock Options and Stock-based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options and Stock Based Compensation [Text Block]	10. Stock Options and Stock-based Compensation In 2002, the Board adopted the 2002 Equity Incentive Plan (the “2002 Plan”) that governed equity awards to employees, directors and consultants of the Company. Under the 2002 Plan, 450,000 4,150,000 5,000,000 The types of awards permitted under the Plans include qualified incentive stock options (ISO), non-qualified stock options (NQO), and restricted stock. Each option shall be exercisable at such times and subject to such terms and conditions as the Board may specify. Stock options generally vest over four years and expire no later than ten years from the date of grant. Shares Weighted Average Weighted Average Remaining Outstanding at December 31, 2014 7,019,750 $ 0.92 6.69 Granted 882,500 $ 0.53 Exercised - $ 0.00 Cancelled or expired (294,687) $ 0.55 Outstanding at June 30, 2015 7,607,563 $ 0.89 6.44 Exercisable at December 31, 2014 4,596,467 $ 1.11 5.95 Exercisable at June 30, 2015 4,983,854 $ 1.08 6.40 Options Outstanding Options Exercisable Exercise Price Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Exercisable Weighted Average Exercise Price $ 0.50 159,000 146,000 $ 0.53 635,000 - $ 0.55 3,844,063 1,868,354 $ 0.80 320,000 320,000 $ 1.25 310,000 310,000 $ 1.50 2,124,750 2,124,750 $ 2.00 214,750 214,750 $0.50 - $2.00 7,607,563 6.44 $ 0.89 4,983,854 $ 1.08 At June 30, 2015, the total aggregate intrinsic value for options currently exercisable and options outstanding was $ 0 0.40 25,000 Shares Weighted Average Grant-date Fair Value Nonvested at December 31, 2014 2,423,283 $ 0.258 Granted 635,000 $ 0.313 Forfeited (294,687) $ 0.251 Vested (139,887) $ 0.386 Nonvested at June 30, 2015 2,623,709 $ 0.237 The fair value of non-vested options to be recognized in future periods is $ 533,923 2.4 159,154 179,049 Six Months Ended June 30, 2015 June 30, 2014 Selling, general, and administrative expense $ 137,092 $ 163,541 Research and development expense 22,062 15,508 Total stock-based compensation expense $ 159,154 $ 179,049 The weighted average grant-date fair value of options granted during the six months ended June 30, 2015 was $ 0.313 0.206 Six Months Ended June 30, 2015 June 30, 2014 Weighted average risk-free interest rate 1.67 % 1.91 % Volatility factor 66.26 % 69.96 % Weighted average expected life (in years) 8 7 Dividend rate 0.0 % 0.0 % The Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar companies considering their industry, stage of life cycle, size, and financial leverage. Given the Company’s limited history with stock options, the Company’s expected term is based on an average of the contractual term and the vesting period of the options (the SAB 110 “Simplified” method).

Stock Warrants

Stock Warrants	6 Months Ended
	Jun. 30, 2015
Stock Warrants [Abstract]
Stock Warrants [Text Block]	11. Stock Warrants From 2008 through 2015, the Company issued warrants to purchase shares of common stock. The warrants are exercisable for five years from date of issuance and are exercisable at exercise prices that range from $ 0.325 2.25 As of June 30, 2015, warrants to purchase 64,338,749 117,041 60,419 98,683 170,418 4,654,145 125,645 49,921 Shares Weighted Average Weighted Average Remaining Outstanding at December 31, 2014 53,112,193 $ 0.98 3.27 Granted 11,978,223 $ 0.38 3.34 Exercised - - Cancelled or expired (751,667) $ 2.00 Outstanding at June 30, 2015 64,338,749 $ 0.86 2.92 0.75 0.64 Warrants Outstanding Exercise Price Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $0.33 7,500,000 $0.38 14,831,098 $0.45 1,730,000 $0.50 1,100,523 $0.64 11,065,144 $0.80 1,415,000 $1.10 19,054,350 $1.12 263,750 $2.00 5,984,175 $2.20 98,320 $2.25 1,296,389 $0.33 - $2.25 64,338,749 2.92 $0.86

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	12. Income Taxes The provision for income taxes, if any, is comprised of current and deferred components. The current component, if any, presents the amount of federal and state income taxes that are currently reportable to the respective tax authorities and is measured by applying statutory rates to the Company’s taxable income as reported in its income tax returns. The Company has evaluated its income tax positions in accordance with FASB ASC 740. There were no changes to unrecognized tax benefits during 2014. The tax years 2011 through 2014 remain open to review by various taxing authorities. ASC Topic 740, Income Taxes greater than 50% likelihood Significant management judgment is required in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded in connection with the deferred tax assets. The Company provides for a full valuation allowance against the deferred tax asset. Net operating loss carryforwards start to expire beginning 2021 for both federal and state purposes 63,500,000 59,800,000

Lease Commitments

Lease Commitments	6 Months Ended
	Jun. 30, 2015
Leases [Abstract]
Lease Commitments [Text Block]	13. Lease Commitments The Company leases its facilities under operating leases beginning a) February 2005 and extended through September 2015 and b) April 2012 through March 2017. The Company also has various equipment operating leases with a term of five years. Year ending December 31: Future required minimum lease payments 2015 (payment in arrears) $ 27,939 2015 (July – December) $ 128,260 2016 $ 172,428 2017 $ 46,707 2018 $ 4,800 2019 $ 4,000 Rent expense totals $ 65,636 142,993 94,220 189,048

Retirement Plan

Retirement Plan	6 Months Ended
	Jun. 30, 2015
Postemployment Benefits [Abstract]
Retirement Plan [Text Block]	14. Retirement Plan The Company provides a 401(k) Profit Sharing Plan (“401(k) Plan”) for elective deferrals whereby participants can defer up to 85% of their wages not to exceed a maximum dollar amount determined by the Federal Government each year.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Legal Matters and Contingencies [Text Block]	15. Commitments and Contingencies Legal Proceedings The Company currently is not a party to any material legal proceeding and has no knowledge of any material legal proceeding contemplated by any governmental authority or third party. The Company may be subject to a number of claims and legal proceedings which, in the opinion of our management, are incidental to normal business operations. In management’s opinion, although final settlement of these claims and suits may impact the financial statements in a particular period, they will not, in the aggregate, have a material adverse effect on the Company’s financial position, cash flows or results of operations. Indemnity of Directors and Officers As permitted under Delaware law and required by corporate by-laws, the Company indemnifies and holds harmless its directors and officers for certain events or occurrences while the director or officer is or was serving in such capacity. The maximum potential amount of future payments that could be required under these indemnification obligations is unlimited; however, the Company maintains a directors and officers liability insurance policy that enables it to recover a portion of any future amounts paid with a limit of liability of $ 5,000,000 Warranty Costs The Company provides for a one year warranty with the sale of its LAESI instrument. All other product warranties are 90 days from the date of delivery of the goods. As the Company does not currently have sufficient historical data on warranty claims, the Company's estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its product. As of June 30, 2015 and December 31,2014, the Company has accrued warranty expense of $ 50,000 University License Agreements The Company has agreements with universities related to in-licensed technologies as follows: AGREEMENT WITH WEST VIRGINIA UNIVERSITY (WVU) The Company has entered into a License and Exclusive Option to License Agreement with the West Virginia University Research Corporation, a nonprofit West Virginia corporation (“WVURC”) acting for and on behalf of WVU. Under the terms of this Agreement, the WVURC has granted the Company an exclusive option to license technology from the laboratories of certain WVU principal investigators in the field of protein discovery, for therapeutic, diagnostic and all other commercial fields worldwide. Under the terms of this Agreement, the Company pays expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenue resulting from the sale of products and services that utilize the WVU subject technology. AGREEMENT WITH GEORGE WASHINGTON UNIVERSITY (GWU) In March 2009, the Company entered into an Exclusive License Agreement with George Washington University (Washington, D.C.) for technology developed in the laboratory of Dr. Akos Vertes Ph.D., Professor of Chemistry, Professor of Biochemistry & Molecular Biology, Founder and Co-Director of the W.M. Keck Institute for Proteomics Technology and Applications, the Department of Chemistry, who is a science advisor Under the terms of the license agreement, the Company has the exclusive, worldwide rights to commercialize the technology. The Company is obligated to pay expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenues resulting from the sale of products and services that utilize the GWU subject technology. During the three and six months ended June 30, 2015, the Company recorded royalty expenses of approximately $ 9,445 20,211 33,433 , of which approximately $ 24,000 29,300 In November 2012, the Company entered into a Patent License Agreement with George Washington University (Washington D.C.) for technology developed in the laboratory of Akos Vertes Ph.D. The technology field is Laser Desorption/Ionization and Peptide Sequencing on Laser-Induced Silicon Microcolumn Arrays (Matrix) and Nanophotonic Production, Modulation and Switching of Ions by Silicon Microcolumn Arrays. Under the terms of the license agreement, the Company has an exclusive, worldwide license to make, have made, use, import, offer for sale and sell the licensed products. The Company is obligated to pay a license initiation fee of $ 25,000 12,500 20,000 30,000 7 5 50 6 4 1,500 2,500 3,500 6,000 As of June 30, 2015, the Company had not reached milestones under this agreement. In January 2014, the Company became a subcontractor to George Washington University in a multi-year project with the Defense Advanced Research Projects Agency (DARPA) to develop new tools and methods to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within 30 days of exposure. AGREEMENT WITH OMICS2IMAGE In 2014, the Company entered into an agreement with Omics2Image related to the “Next Generation Ambient Imaging Mass Spectrometry for (Bio)polymers and Smart Materials” (“COAST Project”). The Company has committed to fund 60,000 40,000 Engineering and Design Services The Company has engaged Dynamic Manufacturing LLC, a contract manufacturer to produce ten LAESI units. As of June 30, 2015, the Company had received five LAESI units from Dynamic. During the second quarter, the Company repaid Dynamic $ 53,063 320,238 0 During the second quarter, the Company received one laser from Bridger Photonics and ordered another laser related to the LAESI technology. The order fully satisfied the Company’s contract with Bridger. The Company prepaid for both lasers. At June 30, 2015, the Company had no remaining commitments with Bridger. At June 30, 2015, the Company owed approximately $ 0

Contingent Acquisition

Contingent Acquisition	6 Months Ended
	Jun. 30, 2015
Contingent Acquisition [Abstract]
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	16. Contingent Acquisition On March 31, 2015, the Company entered into a share purchase agreement, as amended on June 4, 2015 (the “Purchase Agreement”) with the shareholders of vivoPharm Pty. Ltd., a corporation organized under the laws of Australia (“vivoPharm”) to 100 12,063,084 100,000 5,690,280 6,272,804 627,280 10.00 If and when issued, the Company’s Series A Convertible Preferred Stock is convertible by the holder at any time into Company common stock at a conversion price equal to the greater (a) the same price per share at which the Company sells shares of its Common Stock, or the highest conversion price or exercise price per share of any convertible securities, in either case, as issued in connection with the “Required Financing” contemplated by the Purchase Agreement, or (b) forty ($0.40) cents. In addition, the Series A Convertible Preferred Stock is subject to automatic conversion in the event that (a) the volume weighted average price of the Company’s common stock for any 20 consecutive trading days shall equal or exceed 150% of the conversion price then in effect; or (b) the Company shall consummate an underwritten public offering of not less than $15,000,000 of its shares of common stock provided, that Consummation of the vivoPharm acquisition is subject to a number of conditions, including the Company raising not less than $ 10 On June 4, 2015, the Company and vivoPharm agreed to extend the closing date to September 7, 2015. As of the date of this filing, the Company has not raised any funds for the vivoPharm acquisition.

Evaluation of Subsequent Events

Evaluation of Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	17. Evaluation of Subsequent Events Advances from Stockholders Subsequent to June 30, 2015, the Company received advances equal to an aggregate of $ 135,000 1,353,000 Convertible Promissory Note and Commitment Fee Subsequent to June 30, 2015, the Company received an aggregate gross proceeds of $ 200,000 10 0.33 90,910 0.33 Stock Warrants Subsequent to June 30, 2015, the Company issued warrants to purchase 100,000 their continued support of the Company's business development 0.50 Stock Options Subsequent to June 30, 2015, the Company granted options to purchase an aggregate of 150,000 0.48

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Liquidity Policy Text Block [Policy Text Block]	Going Concern The Company’s financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has funded its activities to date almost exclusively from debt and equity financings. The Company will continue to require substantial funds to advance the research and development of its core technologies and to develop new products and services based upon its proprietary protein recovery and identification technologies. Management intends to meet its operating cash flow requirements primarily from the sale of equity and debt securities. The Company seeks additional capital through sales of equity securities or convertible debt and, if appropriate, to pursue partnerships to advance various research and development activities. The Company may also consider the sale of certain assets, or entering into a transaction such as a merger with a business complimentary to theirs. While the Company believes that it will be successful in obtaining the necessary financing to fund its operations, they have no committed sources of funding and are not assured that additional funding will be available to them. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.
Revenue Recognition, Deferred Revenue [Policy Text Block]	Revenue Recognition The Company follows the provisions of FASB ASC 605, “Revenue Recognition.” We recognize revenue of products when persuasive evidence of a sale arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred/title has passed, and collectability of the sales price is reasonably assured. The Company recognizes revenue from the sale of its ProteaPlot™ software when bundled with the LAESI platform, which facilitates operating the instrument and storage and display of datasets. The Company also recognizes revenue of standalone sales of ProteaPlot™, which generally consists of additional user licenses. The Company accounts for shipping and handling costs in accordance with the provisions of FASB ASC 605-45-45, “Revenue Recognition – Principal Agent Considerations,” which requires all amounts charged to customers for shipping and handling to be classified as revenues. Shipping and handling costs charged to customers are recorded in the period the related product sales revenue is recognized. Regarding short-term service contracts, the majority of these service contracts involve the processing of imaging and bioanalytical samples for pharmaceutical and academic/clinical research laboratories. These contracts generally provide for a fixed fee for each method developed or sample processed and revenue is recognized when the analysis is complete and a report is delivered. For longer-term contracts involving multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. We perform this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) have standalone value to the customer and (ii) the delivery or performance of the service(s) is probable and substantially in our control. Revenue on multiple revenue arrangements is recognized using a proportional method for each separately identified element. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or, if there is no predominant deliverable, upon delivery of the final element of the arrangement. Revenues from grants are based upon internal costs that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by the Company that is related to the grants. The Company has revenue from four major components: molecular information services, LAESI instrument platform, research products, and grants and other collaboration revenues. Three Months Ended Six Months Ended June 30, 2015 June 30, 2014 June 30, 2015 June 30, 2014 Molecular Information Services $ 219,064 $ 59,375 $ 389,708 $ 229,945 LAESI Instrument Platform 152,625 140,500 305,987 318,500 Research Products 86,387 120,361 152,910 215,703 Grants and Other Collaborations 53,707 26,325 72,051 50,513 Gross Revenue $ 511,783 $ 346,561 $ 920,656 $ 814,661
Equity Method Investments, Policy [Policy Text Block]	Equity Method Investments The Company’s 33 20 50 The Company determined the fair market value of the investment as having no value as AzurRx is still in early stages of organizing, has not reached commercialization, and will continue realizing substantial research and development expenses. In addition, the Company has suspended the equity method of accounting, as the losses have reduced the Company’s basis in AzurRx below zero. The value of this investment as presented on our consolidated balance sheet was $ 0
Other Receivables and Other Noncurrent assets [Policy Text Block]	Other Receivables and Other Noncurrent Assets June 30, 2015 December 31, 2014 Other receivables $ - $ 119,230 Other receivables – current $ - $ 119,230 Deposits $ 105,248 $ 136,693 Other assets – noncurrent $ 105,248 $ 136,693
Other Payables and Accrued Expenses [Policy Text Block]	Other Payables and Accrued Expenses June 30, 2015 December 31, 2014 Accrued expenses $ 56,564 $ 31,104 Accrued interest 98,424 201,844 Accrued warranties 50,000 50,000 Accrued payroll and benefits 233,055 219,973 Unearned revenue 60,758 15,900 Other payables and accrued expenses $ 498,801 $ 518,821
Derivatives, Embedded Derivatives [Policy Text Block]	Derivative Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks; however, the Company has certain financial instruments that are embedded derivatives associated with capital raises and common stock purchase warrants. The Company evaluates all of its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 815-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity.
Fair Value Measurement, Policy [Policy Text Block]	We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities. Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable. Level 3 – inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of common stock warrants). The Company has entered into certain financial instruments and contracts such as equity financing arrangements for the issuance of common stock, which include anti-dilution arrangements “Down Round Protection” and detachable stock warrants that are i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are recorded as derivative liabilities at fair value at the issuance date. Subsequent changes in fair value are recorded through the Statement of Comprehensive Loss. June 30, 2015 Expected Life (Years) Risk Free Rate Volatility Probability of a Capital Raise Derivative liabilities 2.37-3.83 1.01 % 74.57 % 100 % Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company’s derivative liabilities are related to common stock issuances, detachable warrants issued in conjunction with debt and common stock, or warrants issued to the placement agents for financial instrument issuances. Fair Value Measurements at June 30, 2015 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities – common stock - - - - Derivative liabilities – warrants 75,794 - - 75,794 Total $ 75,794 - - $ 75,794 For the quarter ended June 30, 2015, the Company modified its assessment of the probability of future down-rounds, due to a high probability of closing on a subsequent capital raises at levels that would not result in anti-dilution triggers, currently at $ 0.25 Fair Value Measurements at December 31, 2014 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities – common stock $ 88,871 - - $ 88,871 Derivative liabilities – warrants 65,187 - - 65,187 Total $ 154,058 - - $ 154,058 As a result of the 2014 winter offering, the Company issued 15,524,642 10,122,067 1,771,362 5,402,575 945,451 Six Months Ended June 30, 2015 Derivative Liabilities - Common Stock Derivative Total Fair Value Measurements Using Level 3 Balance at January 1, 2015 $ 88,871 $ 65,187 $ 154,058 Issuance of warrants - 5,948 5,948 Anti-dilution shares issued (945,451) (945,451) Unrealized loss on derivative liabilities 856,580 (20,398) 836,182 Recognition of derivative liabilities - 25,057 25,057 Balance at June 30, 2015 $ - $ 75,794 $ 75,794 Year Ended December 31, 2014 Derivative Liabilities - Common Stock Derivative Total Fair Value Measurements Using Level 3 Beginning balance at January 1, 2014 $ 558,799 $ 64,788 $ 623,587 Issuance of warrants - 2,550 2,550 Anti-dilution shares to be issued (1,771,362) - (1,771,362) Unrealized (gain) loss on derivative liabilities 1,301,434 (11,449) 1,289,985 Recognition of derivative liabilities - 9,298 9,298 Balance at December 31, 2014 $ 88,871 $ 65,187 $ 154,058
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Common share equivalents (which may consist of options, warrants and convertible debt) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 79,823,000 84,834,000
New Accounting Pronouncements, Policy [Policy Text Block]	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS: In May 2014, the FASB issued a standard on revenue recognition that provides a single, comprehensive revenue recognition model for all contracts with customers. The standard is principle-based and provides a five-step model to determine the measurement of revenue and timing of when it is recognized. The core principle is that a company will recognize revenue to reflect the transfer of goods or services to customers at an amount that the company expects to be entitled to in exchange for those goods or services. This standard is to be applied retrospectively and is effective for fiscal years beginning after December 15, 2017 as deferred by the FASB in July 2015. The Company is evaluating the impact that this standard will have on its consolidated financial statements. In June 2014, the FASB issued authoritative guidance on stock compensation, which requires performance targets that affect vesting and can be achieved after the requisite service period, to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If achievement of the performance target becomes probable before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The amendments are effective for fiscal years beginning after December 15, 2015. The Company is evaluating the impact that this standard will have on its consolidated financial statements. In August 2014, the FASB issued authoritative guidance on going concern disclosures and financial statement presentation, which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). This standard provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the financial statement footnotes. This standard is effective for annual reporting periods ending after December 15, 2016, and to annual and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements and related disclosures. In November, 2014, the FASB issued ASU 2014-16, "Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force)." The ASU clarifies how current guidance should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of a host contract. The ASU is effective for fiscal years and interim periods beginning after December 15, 2015. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements. In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs”. This standard update requires an entity to present debt issuance costs on the balance sheet as a direct deduction from the related debt liability as opposed to an asset. Amortization of the costs will continue to be reported as interest expense. The update is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued, and the new guidance would be applied retrospectively to all prior periods presented. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements and related disclosures. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory”. This standard requires that inventory be valued at the lower of cost or net realizable value, which is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update is effective for fiscal years beginning after December 14, 2016, including interim periods within those fiscal years. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Revenue from External Customers by Products and Services [Table Text Block]	Revenue by component was as follows: Three Months Ended Six Months Ended June 30, 2015 June 30, 2014 June 30, 2015 June 30, 2014 Molecular Information Services $ 219,064 $ 59,375 $ 389,708 $ 229,945 LAESI Instrument Platform 152,625 140,500 305,987 318,500 Research Products 86,387 120,361 152,910 215,703 Grants and Other Collaborations 53,707 26,325 72,051 50,513 Gross Revenue $ 511,783 $ 346,561 $ 920,656 $ 814,661
Summary of Trade and Other Receivables [Table Text Block]	Other assets, which reflect amounts due from non-trade activity, consist of the following at: June 30, 2015 December 31, 2014 Other receivables $ - $ 119,230 Other receivables – current $ - $ 119,230 Deposits $ 105,248 $ 136,693 Other assets – noncurrent $ 105,248 $ 136,693
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Other payables and accrued expenses, which reflect amounts due from non-trade activity, consist of the following at: June 30, 2015 December 31, 2014 Accrued expenses $ 56,564 $ 31,104 Accrued interest 98,424 201,844 Accrued warranties 50,000 50,000 Accrued payroll and benefits 233,055 219,973 Unearned revenue 60,758 15,900 Other payables and accrued expenses $ 498,801 $ 518,821
Fair Value Inputs, Instruments Classified in Shareholders Equity, Quantitative Information [Table Text Block]	A range of key quantitative assumptions related to the common stock and warrants that include “Down Round Protection” are as follows: June 30, 2015 Expected Life (Years) Risk Free Rate Volatility Probability of a Capital Raise Derivative liabilities 2.37-3.83 1.01 % 74.57 % 100 %
Fair Value, by Balance Sheet Grouping [Table Text Block]	The derivative liabilities measured at fair value on a recurring basis are summarized below: Fair Value Measurements at June 30, 2015 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities – common stock - - - - Derivative liabilities – warrants 75,794 - - 75,794 Total $ 75,794 - - $ 75,794 Fair Value Measurements at December 31, 2014 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities – common stock $ 88,871 - - $ 88,871 Derivative liabilities – warrants 65,187 - - 65,187 Total $ 154,058 - - $ 154,058
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis: Six Months Ended June 30, 2015 Derivative Liabilities - Common Stock Derivative Total Fair Value Measurements Using Level 3 Balance at January 1, 2015 $ 88,871 $ 65,187 $ 154,058 Issuance of warrants - 5,948 5,948 Anti-dilution shares issued (945,451) (945,451) Unrealized loss on derivative liabilities 856,580 (20,398) 836,182 Recognition of derivative liabilities - 25,057 25,057 Balance at June 30, 2015 $ - $ 75,794 $ 75,794 Year Ended December 31, 2014 Derivative Liabilities - Common Stock Derivative Total Fair Value Measurements Using Level 3 Beginning balance at January 1, 2014 $ 558,799 $ 64,788 $ 623,587 Issuance of warrants - 2,550 2,550 Anti-dilution shares to be issued (1,771,362) - (1,771,362) Unrealized (gain) loss on derivative liabilities 1,301,434 (11,449) 1,289,985 Recognition of derivative liabilities - 9,298 9,298 Balance at December 31, 2014 $ 88,871 $ 65,187 $ 154,058

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Finished goods and work in progress consist primarily of specifically identifiable items that are valued at the lower of cost or fair market value using the first-in, first-out (FIFO) method. Inventory consists of the following at: Inventory: June 30, 2015 December 31, 2014 Finished goods $ 14,992 $ 18,739 Work in progress 41,503 142,562 Total Inventory $ 56,495 $ 161,301

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property Plant And Equipment Useful Life [Table Text Block]	Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows: Equipment 5 - 10 years Vehicle 5 years Leasehold improvements Life of lease Software 3 years
Property, Plant and Equipment [Table Text Block]	Property and equipment consists of the following at: June 30, 2015 December 31, 2014 Lab equipment $ 7,011,067 $ 7,313,979 Computer equipment 540,212 540,814 Office equipment 191,248 229,785 Leasehold improvements 443,639 434,304 8,186,166 8,518,882 Accumulated depreciation (5,143,678) (5,558,792) Property and equipment, net $ 3,042,488 $ 2,960,090

Short and Long-term Debt (Table

Short and Long-term Debt (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	Total debts outstanding are as follows: June 30, 2015 December 31, 2014 1) Note Payable to the WVDO $ 100,656 $ 99,365 2) Note Payable to the WVEDA 143,312 141,369 3) Note Payable to the WVIJDC 139,229 139,128 4) Note Payable to the WVEDA 572,148 617,767 5) Note Payable to the WVIJDC 581,987 630,738 6) Note Payable to the WVJITB 290,000 290,000 7) Note Payable to the WVJITB 300,000 300,000 8) Note Payable to the WVHTCF 47,863 69,888 9) Note Payable to the WVEDA 168,362 166,258 10) Convertible Debentures 2,500,000 - 11) Capital leases 1,043,572 820,524 Total 5,887,129 3,275,037 Less: current portion (2,716,926) (1,457,800) Less: unamortized discount (735,598) - Less: transaction costs (309,344) - Long-term portion $ 2,125,261 $ 1,817,237
Schedule of Maturities of Long-term Debt [Table Text Block]	Future required minimum principal repayments over the next five years are as follows: Year Ending December 31: Future Required 2015 $ 3,444,045 2016 739,424 2017 556,334 2018 371,822 2019 & Thereafter 775,504 Total $ 5,887,129

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2015
Common Stock [Member]
Schedule of Stock by Class [Table Text Block]	The members of the Board of Directors are elected by the affirmative vote of the holders of a majority of the Company’s outstanding Common Stock. Common Stock issued are as follows: # Shares Par Price Gross Value of Services Obtained Par Additional Paid in Capital (1) Balance at December 31, 2014 66,588,600 $ .0001 Various $ 53,708,521 $ 1,814,673 $ 6,659 $ 55,516,535 Issuance of stock (2) 2,201,046 .0001 $ 0.25 550,261 - 220 550,041 Issuance of stock (3) 30,286,520 .0001 $ 0.25 - - 3,029 (2,650) Issuance of stock (4) 15,524,642 .0001 $ 0.25 - - 1,552 (1,552) Issuance of stock (5) 300,000 .0001 $ 0.31 - $ 93,000 30 92,970 Balance at June 30, 2015 114,900,808 $ 54,258,782 $ 1,907,673 $ 11,490 $ 56,155,344 (1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options. (2) Shares issued for conversion of an aggregate of $ 341,085 192,785 16,391 (3) Shares issued upon conversion of preferred stock and accrued dividends thereon and contained an anti-dilution provision. (4) Shares issued under certain anti-dilution privileges. (5) Shares issued to a consultant for services rendered. Shares do not contain anti-dilution provision.

Preferred Stock (Tables)

Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2015
Preferred Stock [Member]
Schedule of Stock by Class [Table Text Block]	No shares of the Preferred Stock were issued prior to 2014. # Shares Par Price Gross Par Additional Paid in Capital (1) Balance at December 31, 2014 3,337,725 $ .0001 $ 2.00 $ 6,675,452 $ 334 $ 6,675,118 Issuance of stock (2) 370,050 .0001 $ 2.00 740,100 37 740,063 Stock dividend 78,040 .0001 $ 2.00 (156,056) 8 156,048 Conversion of preferred stock (3,785,815) .0001 $ 2.00 (7,259,496) (379) (7,571,229) Balance at June 30, 2015 - $ - $ - $ - (1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options. (2) Shares issued contain an anti-dilution provision expiring upon the conversion to common stock.

Stock Options and Stock-based32

Stock Options and Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Shares Weighted Average Weighted Average Remaining Outstanding at December 31, 2014 7,019,750 $ 0.92 6.69 Granted 882,500 $ 0.53 Exercised - $ 0.00 Cancelled or expired (294,687) $ 0.55 Outstanding at June 30, 2015 7,607,563 $ 0.89 6.44 Exercisable at December 31, 2014 4,596,467 $ 1.11 5.95 Exercisable at June 30, 2015 4,983,854 $ 1.08 6.40
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information about stock options at June 30, 2015: Options Outstanding Options Exercisable Exercise Price Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Exercisable Weighted Average Exercise Price $ 0.50 159,000 146,000 $ 0.53 635,000 - $ 0.55 3,844,063 1,868,354 $ 0.80 320,000 320,000 $ 1.25 310,000 310,000 $ 1.50 2,124,750 2,124,750 $ 2.00 214,750 214,750 $0.50 - $2.00 7,607,563 6.44 $ 0.89 4,983,854 $ 1.08
Schedule of Nonvested Share Activity [Table Text Block]	The following table summarizes the activity of the Company’s stock options that have not vested: Shares Weighted Average Grant-date Fair Value Nonvested at December 31, 2014 2,423,283 $ 0.258 Granted 635,000 $ 0.313 Forfeited (294,687) $ 0.251 Vested (139,887) $ 0.386 Nonvested at June 30, 2015 2,623,709 $ 0.237
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense is as follows: Six Months Ended June 30, 2015 June 30, 2014 Selling, general, and administrative expense $ 137,092 $ 163,541 Research and development expense 22,062 15,508 Total stock-based compensation expense $ 159,154 $ 179,049
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the option grants was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions: Six Months Ended June 30, 2015 June 30, 2014 Weighted average risk-free interest rate 1.67 % 1.91 % Volatility factor 66.26 % 69.96 % Weighted average expected life (in years) 8 7 Dividend rate 0.0 % 0.0 %

Stock Warrants (Tables)

Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2015
Stock Warrants [Abstract]
Schedule Of Warrant Activity [Table Text Block]	the Company recognized a total of $ 125,645 49,921 Shares Weighted Average Weighted Average Remaining Outstanding at December 31, 2014 53,112,193 $ 0.98 3.27 Granted 11,978,223 $ 0.38 3.34 Exercised - - Cancelled or expired (751,667) $ 2.00 Outstanding at June 30, 2015 64,338,749 $ 0.86 2.92
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	As a result of the 2014 Winter Offering, the exercise price of the 2013 Winter Offering warrants was adjusted from $ 0.75 0.64 Warrants Outstanding Exercise Price Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $0.33 7,500,000 $0.38 14,831,098 $0.45 1,730,000 $0.50 1,100,523 $0.64 11,065,144 $0.80 1,415,000 $1.10 19,054,350 $1.12 263,750 $2.00 5,984,175 $2.20 98,320 $2.25 1,296,389 $0.33 - $2.25 64,338,749 2.92 $0.86

Lease Commitments (Tables)

Lease Commitments (Tables)	6 Months Ended
	Jun. 30, 2015
Leases [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future required minimum principal repayments over the next five years are as follows: Year ending December 31: Future required minimum lease payments 2015 (payment in arrears) $ 27,939 2015 (July – December) $ 128,260 2016 $ 172,428 2017 $ 46,707 2018 $ 4,800 2019 $ 4,000

Summary of Significant Accoun35

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Gross Revenue	$ 511,783	$ 346,561	$ 920,656	$ 814,661
Molecular Information Services [Member]
Segment Reporting Information [Line Items]
Gross Revenue	219,064	59,375	389,708	229,945
LAESI Instrument Platform [Member]
Segment Reporting Information [Line Items]
Gross Revenue	152,625	140,500	305,987	318,500
Research Products [Member]
Segment Reporting Information [Line Items]
Gross Revenue	86,387	120,361	152,910	215,703
Grants and Other Collaborations [Member]
Segment Reporting Information [Line Items]
Gross Revenue	$ 53,707	$ 26,325	$ 72,051	$ 50,513

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Details 1) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Other receivables	$ 0	$ 119,230
Other receivables - current	0	119,230
Deposits	105,248	136,693
Other assets - noncurrent	$ 105,248	$ 136,693

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Details 2) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Payables And Accruals [Line Items]
Accrued expenses	$ 56,564	$ 31,104
Accrued interest	98,424	201,844
Accrued warranties	50,000	50,000
Accrued payroll and benefits	233,055	219,973
Unearned revenue	60,758	15,900
Other payables and accrued expenses	$ 498,801	$ 518,821

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Details 3) - 6 months ended Jun. 30, 2015	Total
Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Expected Life (Years)	3 years 9 months 29 days
Derivative Financial Instruments, Liabilities [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Risk Free Rate	1.01%
Fair Value Assumptions, Volatility	74.57%
Probability of a Capital Raise	100.00%
Derivative Financial Instruments, Liabilities [Member] | Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Expected Life (Years)	2 years 4 months 13 days

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Details 4) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	$ 75,794	$ 154,058
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	75,794	154,058	$ 623,587
Derivative liabilities - common stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	88,871	558,799
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	88,871
Derivative liabilities - warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	75,794	65,187	$ 64,788
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	$ 75,794	$ 65,187

Summary of Significant Accoun40

Summary of Significant Accounting Policies (Details 5) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	$ 154,058
Issuance of warrants	191,683	$ 515,463
Ending balance	75,794		$ 154,058
Derivative liabilities - warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	65,187	64,788	64,788
Issuance of warrants	5,948		2,550
Anti-dilution shares issued			0
Unrealized (gain) loss on derivative liabilities	(20,398)		(11,449)
Recognition of derivative liabilities	25,057		9,298
Ending balance	75,794		65,187
Derivative liabilities - common stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	88,871	558,799	558,799
Issuance of warrants	0		0
Anti-dilution shares issued	(945,451)		(1,771,362)
Unrealized (gain) loss on derivative liabilities	856,580		1,301,434
Recognition of derivative liabilities	0		0
Ending balance	0		88,871
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	154,058	$ 623,587	623,587
Issuance of warrants	5,948		2,550
Anti-dilution shares issued	(945,451)		(1,771,362)
Unrealized (gain) loss on derivative liabilities	836,182		1,289,985
Recognition of derivative liabilities	25,057		9,298
Ending balance	75,794		154,058
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	65,187
Ending balance	75,794		65,187
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - common stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	88,871
Ending balance	$ 0		$ 88,871

Summary of Significant Accoun41

Summary of Significant Accounting Policies (Details Textual) - Equity Component [Domain] - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	May. 31, 2015	Jun. 30, 2015	Jun. 30, 2015	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			79,823,000	84,834,000
Stock Issued During Period, Shares, Other	5,402,575	15,524,642		10,122,067
Stock Issued During Period, Value, Other	$ 945,451		$ 945,451	$ 1,771,362
Anti Dilutive Trigger Price			0.25%
Maximum [Member]
Significant Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage		50.00%	50.00%
Minimum [Member]
Significant Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage		20.00%	20.00%
AzurRx BioPharma Inc [Member]
Significant Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage		33.00%	33.00%
Equity Method Investments		$ 0	$ 0	$ 0

Inventory (Details)

Inventory (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Inventory:
Finished goods	$ 14,992	$ 18,739
Work in progress	41,503	142,562
Total Inventory	$ 56,495	$ 161,301

Property and Equipment (Details

Property and Equipment (Details)	6 Months Ended
	Jun. 30, 2015
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Life of lease

Property and Equipment (Detai44

Property and Equipment (Details 1) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Lab equipment	$ 7,011,067	$ 7,313,979
Computer equipment	540,212	540,814
Office equipment	191,248	229,785
Leasehold improvements	443,639	434,304
Property, Plant and Equipment, Gross	8,186,166	8,518,882
Accumulated depreciation	(5,143,678)	(5,558,792)
Property and equipment, net	$ 3,042,488	$ 2,960,090

Property and Equipment (Detai45

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Depreciation, Depletion and Amortization, Total	$ 181,084	$ 224,455	$ 356,055	$ 430,771

Bank Line of Credit (Details Te

Bank Line of Credit (Details Textual) - Jun. 30, 2015 - USD ($)	Total
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity (in dollars)	$ 3,000,000
Line of Credit Facility, Interest Rate Description	The interest rate is variable and is .75% plus prime with a minimum rate of 5.87%.
Line of Credit Facility, Amount Outstanding (in dollars)	$ 3,000,000
Line of Credit Facility, Interest Rate at Period End	5.87%

Loans Payable to Stockholders (

Loans Payable to Stockholders (Details Textual) - Relationship to Entity [Domain] - Subsequent Event Type [Domain] - Equity Component [Domain] - USD ($)	1 Months Ended			3 Months Ended	12 Months Ended
	May. 31, 2015	Mar. 20, 2015	Aug. 06, 2013	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2015	Jun. 03, 2014
Loans Payable to Stockholders [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.375
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						200,000
Due to Officers or Stockholders, Current					$ 1,381,498	$ 2,135,000
Payments of Debt Issuance Costs	$ 309,344
Related Party Remaining Debt					$ 170,000
Loans Payable [Member]
Loans Payable to Stockholders [Line Items]
Payments of Debt Issuance Costs				$ 28,964
Loans Payable One [Member]
Loans Payable to Stockholders [Line Items]
Payments of Debt Issuance Costs				31,455
Convertible One-year Promissory Note [Member]
Loans Payable to Stockholders [Line Items]
Debt Instrument, Interest Rate, Effective Percentage					10.00%
Summit Resources Inc [Member] | Notes And Warrants 2013 [Member]
Loans Payable to Stockholders [Line Items]
Warrants Issued to Purchase of Common Stock, Shares			1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.50	$ 1.10
Debt Instrument, Face Amount			$ 600,000
Debt Instrument, Interest Rate, Effective Percentage			10.00%
Repayments of Debt					$ 423,915
Accretion Expense				39,360	$ 94,757
Debt Conversion, Converted Instrument, Shares Issued		1,055,165
Warrants and Rights Outstanding			$ 134,117
Debt Conversion, Original Debt, Amount		$ 176,085
Debt Instrument, Increase, Accrued Interest		$ 87,707
Debt Instrument, Convertible, Conversion Price		$ 0.25
Debt Conversion, Converted Instrument, Warrants or Options Issued		527,583
Summit Resources Inc [Member] | Notes And Warrants 2014 [Member]
Loans Payable to Stockholders [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.80
Debt Instrument, Face Amount					$ 1,415,000
Repayments of Debt					250,000
Accretion Expense				7,227	10,950
Loans Payable					1,074,773
Due to Related Parties, Current					$ 1,415,000
Debt Conversion, Converted Instrument, Shares Issued		1,080,312
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		0.50			1,415,000
Warrants and Rights Outstanding							$ 101,177
Debt Conversion, Original Debt, Amount		$ 165,000
Debt Instrument, Increase, Accrued Interest		$ 105,078
Debt Instrument, Convertible, Conversion Price		$ 0.25
Debt Conversion, Converted Instrument, Warrants or Options Issued		540,156
Due To Officers Or Stock holders Current Net Of Discount						917,000
Due to Officers or Stockholders, Current						1,000,000
Summit Resources Inc [Member] | Maximum [Member] | Notes And Warrants 2013 [Member]
Loans Payable to Stockholders [Line Items]
Proceeds from Sale of Other Property, Plant, and Equipment				$ 150,000
Summit Resources Inc [Member] | Maximum [Member] | Notes And Warrants 2014 [Member]
Loans Payable to Stockholders [Line Items]
Long-term Debt, Gross							1,500,000
Summit Resources Inc [Member] | Minimum [Member] | Notes And Warrants 2014 [Member]
Loans Payable to Stockholders [Line Items]
Long-term Debt, Gross							$ 900,000
Directors and Stock holders [Member]
Loans Payable to Stockholders [Line Items]
Due to Related Parties, Current						$ 1,048,000
Due to Affiliate					$ 540,000
Repayments of Related Party Debt					$ 370,000

Short and Long-term Debt (Detai

Short and Long-term Debt (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	$ 5,887,129	$ 3,275,037
Less: current portion	(2,716,926)	(1,457,800)
Less: unamortized discount	(735,598)	0
Less: transaction costs	(309,344)	0
Long-term portion	2,125,261	1,817,237
Unsecured Convertible Debentures [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	2,500,000	0
Note Payable To West Virginia Development Office [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	100,656	99,365
Note Payable To West Virginia Economic Development Authority, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	143,312	141,369
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	139,229	139,128
Note Payable To West Virginia Economic Development Authority, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	572,148	617,767
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	581,987	630,738
Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	290,000	290,000
Note Payable To West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	300,000	300,000
Note Payable To West Virginia High Technology Consortium Foundation [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	47,863	69,888
Note Payable to West Virginia Economic Development Authority, Series 3 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	168,362	166,258
Capital leases [Member]
Debt Instrument [Line Items]
Capital Lease Obligations	$ 1,043,572	$ 820,524

Short and Long-term Debt (Det49

Short and Long-term Debt (Details 1) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Future Required Minimum Principal Repayments
2,015	$ 3,444,045
2,016	739,424
2,017	556,334
2,018	371,822
2019 & Thereafter	775,504
Total	$ 5,887,129	$ 3,275,037

Short and Long-term Debt (Det50

Short and Long-term Debt (Details Textual) - Relationship to Entity [Domain] - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

May. 31, 2015

Apr. 15, 2015

Dec. 31, 2013

Jun. 30, 2012

May. 31, 2012

Apr. 30, 2012

Mar. 31, 2012

Dec. 31, 2010

Oct. 31, 2010

Aug. 31, 2009

Mar. 31, 2007

Mar. 31, 2015

Jun. 30, 2015

Dec. 31, 2014

Debt Instrument [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

200,000

Common Stock, Par or Stated Value Per Share

$ 0.0001

$ 0.0001

Unsecured Convertible Debentures [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Maturity Date

Nov. 22, 2015

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

7,500,000

Debt Instrument, Convertible, Conversion Price

$ 0.25

Debt Instrument, Face Amount

$ 2,500,000

Unsecured Debt Original Issue Discount Percentage

20.00%

Proceeds from Issuance of Unsecured Debt

$ 2,000,000

Common Stock, Par or Stated Value Per Share

$ 0.325

Accretion Expense

$ 68,625

Interest Expense, Debt

107,527

Short-term Debt, Maximum Amount Outstanding During Period

2,500,000

Short-term Debt

$ 1,455,058

Warrants Expiration Term

3 years

Unsecured Convertible Debentures [Member] | Warrant [Member]

Debt Instrument [Line Items]

Common Stock, Par or Stated Value Per Share

$ 0.001

Warrants Not Settleable in Cash, Fair Value Disclosure

$ 411,750

Notes Payable to West Virginia Development Office [Member]

Debt Instrument [Line Items]

Duration of Debt Instrument

8 years

Long-term Debt, Gross (in dollars)

$ 685,000

Debt Instrument, Interest Rate, Stated Percentage

3.00%

Number of Debt Instrument Periodic Payments

96 months

Debt Instrument, Periodic Payment

$ 8,035

Pledged Assets, Not Separately Reported, Other

$ 1,057,167

Debt Instrument, Maturity Date

Apr. 30, 2015

Debt Instrument, Collateral

The note was secured by equipment

Notes Payable to West Virginia Economic Development Authority, Series 1 [Member]

Debt Instrument [Line Items]

Duration of Debt Instrument

10 years

Long-term Debt, Gross (in dollars)

$ 242,631

Debt Instrument, Interest Rate, Stated Percentage

4.00%

Number of Debt Instrument Periodic Payments

120 months

Debt Instrument, Periodic Payment

$ 2,457

Pledged Assets, Not Separately Reported, Other

$ 531,522

Debt Instrument, Maturity Date

Aug. 31, 2019

Debt Instrument, Collateral

The note was secured by 50% of equipment

Debt Instrument, Annual Principal Payment

33,880

Debt Instrument, Interest Rate, Increase (Decrease)

1.50%

Note Payable to West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]

Debt Instrument [Line Items]

Duration of Debt Instrument

10 years

Long-term Debt, Gross (in dollars)

$ 242,630

Debt Instrument, Interest Rate, Stated Percentage

3.25%

Number of Debt Instrument Periodic Payments

120 months

Debt Instrument, Periodic Payment

$ 2,371

Pledged Assets, Not Separately Reported, Other

$ 531,522

Debt Instrument, Maturity Date

Aug. 31, 2019

Debt Instrument, Collateral

The note was secured by 50% of equipment

Note Payable to West Virginia Economic Development Authority, Series 2 [Member]

Debt Instrument [Line Items]

Duration of Debt Instrument

10 years

Long-term Debt, Gross (in dollars)

$ 900,000

Debt Instrument, Interest Rate, Stated Percentage

3.26%

Number of Debt Instrument Periodic Payments

120 months

Debt Instrument, Periodic Payment

$ 8,802

Pledged Assets, Not Separately Reported, Other

$ 477,095

Debt Instrument, Maturity Date

Oct. 31, 2020

Debt Instrument, Collateral

The note was secured by equipment

Debt Instrument, Annual Principal Payment

$ 125,990

Debt Instrument, Interest Rate, Increase (Decrease)

1.50%

Note Payable to West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]

Debt Instrument [Line Items]

Duration of Debt Instrument

10 years

Long-term Debt, Gross (in dollars)

$ 900,000

Debt Instrument, Interest Rate, Stated Percentage

3.25%

Number of Debt Instrument Periodic Payments

120 months

Debt Instrument, Periodic Payment

$ 8,781

Pledged Assets, Not Separately Reported, Other

$ 1,098,249

Debt Instrument, Maturity Date

Dec. 31, 2020

Debt Instrument, Collateral

The note was secured by equipment

Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member]

Debt Instrument [Line Items]

Duration of Debt Instrument

18 months

Long-term Debt, Gross (in dollars)

$ 290,000

Debt Instrument, Interest Rate, Stated Percentage

6.00%

Debt Instrument, Maturity Date

Sep. 30, 2013

Debt Instrument, Payment Terms

monthly interest-only payments starting May 2012 through June 2012, then final interest and principal payments due July 2012

monthly interest-only payments starting April 2012 through August 2013, then final interest and principal payments due September 2013

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

72,500

Debt Instrument, Convertible, Conversion Price

$ 2

Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member] | Due on March 15, 2014 [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment

$ 100,000

Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member] | Due on June 15, 2014 [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment

$ 190,000

Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 2 [Member]

Debt Instrument [Line Items]

Duration of Debt Instrument

3 months

Long-term Debt, Gross (in dollars)

$ 400,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Maturity Date

Jul. 31, 2012

Debt Instrument, Periodic Payment, Principal

$ 100,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

88,889

Debt Instrument, Convertible, Conversion Price

$ 0.50

Debt Instrument, Face Amount

$ 300,000

Convertible Promissory Note Payable to West Virginia High Technology Consortium Foundation [Member]

Debt Instrument [Line Items]

Duration of Debt Instrument

30 months

Long-term Debt, Gross (in dollars)

$ 74,726.08

$ 200,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Number of Debt Instrument Periodic Payments

25 months

Debt Instrument, Periodic Payment

$ 8,789.37

$ 9,001

Pledged Assets, Not Separately Reported, Other

$ 447,320

Debt Instrument, Maturity Date

Dec. 31, 2014

Dec. 31, 2014

Debt Instrument, Collateral

The note is secured by 50% of equipment

Note Payable to West Virginia Economic Development Authority, Series 3 [Member]

Debt Instrument [Line Items]

Duration of Debt Instrument

10 years

Long-term Debt, Gross (in dollars)

$ 200,000

Debt Instrument, Interest Rate, Stated Percentage

2.00%

Number of Debt Instrument Periodic Payments

120 months

Debt Instrument, Periodic Payment

$ 1,840

Pledged Assets, Not Separately Reported, Other

$ 447,320

Debt Instrument, Maturity Date

Jun. 30, 2022

Debt Instrument, Collateral

The note was secured by 50% of equipment

Debt Instrument, Annual Principal Payment

$ 26,673

Debt Instrument, Interest Rate, Increase (Decrease)

1.50%

Capital Leases [Member]

Debt Instrument [Line Items]

Lease Expiration Date

December 2016 through October 2019.

Capital Lease Obligation Collateral

secured by equipment with an aggregate cost of $1,580,257.

Capital Leases [Member] | Maximum [Member]

Debt Instrument [Line Items]

Imputed Interest Rate

6.00%

Capital Leases [Member] | Minimum [Member]

Debt Instrument [Line Items]

Imputed Interest Rate

5.86%

Common Stock (Details)

Common Stock (Details) - USD ($)		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Class of Stock [Line Items]
Balance at December 31, 2014, Par Value (in dollars per share)		$ 0.0001		$ 0.0001
Issuance of stock, Gross Proceeds (in dollars)		$ 0	$ (12,500)
Balance		6,659
Issuance of stock for services		93,000
Balance		$ 11,490
Common Stock [Member]
Class of Stock [Line Items]
Balance (in shares)		66,588,600
Issuance of stock, Shares issued (in shares)		300,000
Balance (in shares)		114,900,808
Balance at December 31, 2014, Par Value (in dollars per share)		$ 0.0001
Balance at December 31, 2014, Price Per Share (in dollars per share)		Various
Balance at December 31, 2014, Gross Proceeds (in dollars)		$ 53,708,521
Balance at June 30.2015, Gross Proceeds (in dollars)		54,258,782
Balance at December 31, 2014, Value of Services Obtained (in dollars)		1,814,673
Balance at June 30, 2015, Value of Services Obtained (in dollars)		1,907,673
Balance		6,659
Issuance of stock for services		30
Balance		11,490
Balance at December 31, 2014, Additional Paid in Capital (in dollars)	[1]	55,516,535
Balance at June 30, 2015, Additional Paid in Capital (in dollars)	[1]	$ 56,155,344
Issuance of stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[2]	2,201,046
Issuance of stock, Par Value (in dollars per share)	[2]	$ 0.0001
Stock Options exercised, Price Per Share (in dollars per share)	[2]	$ 0.25
Issuance of stock, Gross Proceeds (in dollars)	[2]	$ 550,261
Issuance of stock, Value of Services Obtained (in dollars)	[2]	0
Issuance of stock for services	[2]	220
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[2]	$ 550,041
Issuance of stock 1 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[3]	30,286,520
Issuance of stock, Par Value (in dollars per share)	[3]	$ 0.0001
Stock Options exercised, Price Per Share (in dollars per share)	[3]	$ 0.25
Issuance of stock, Gross Proceeds (in dollars)	[3]	$ 0
Issuance of stock, Value of Services Obtained (in dollars)	[3]	0
Issuance of stock for services	[3]	3,029
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[3]	$ (2,650)
Issuance of stock 2 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[4]	15,524,642
Issuance of stock, Par Value (in dollars per share)	[4]	$ 0.0001
Stock Options exercised, Price Per Share (in dollars per share)	[4]	$ 0.25
Issuance of stock, Gross Proceeds (in dollars)	[4]	$ 0
Issuance of stock, Value of Services Obtained (in dollars)	[4]	0
Issuance of stock for services	[4]	1,552
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[4]	$ (1,552)
Issuance of stock 3 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[5]	300,000
Issuance of stock, Par Value (in dollars per share)	[5]	$ 0.0001
Stock Options exercised, Price Per Share (in dollars per share)	[5]	$ 0.31
Issuance of stock, Gross Proceeds (in dollars)	[5]	$ 0
Issuance of stock, Value of Services Obtained (in dollars)	[5]	93,000
Issuance of stock for services	[5]	30
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[5]	$ 92,970
[1]	Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
[2]	Shares issued for conversion of an aggregate of $341,085 principal amount and $192,785 of accrued interest on promissory notes and $16,391 of accounts payable. Shares do not contain an anti-dilution provision.
[3]	Shares issued upon conversion of preferred stock and accrued dividends thereon and contained an anti-dilution provision.
[4]	Shares issued under certain anti-dilution privileges.
[5]	Shares issued to a consultant for services rendered. Shares do not contain anti-dilution provision.

Common Stock (Details Textual)

Common Stock (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Class of Stock [Line Items]
Shares Authorized Total	260,000,000
Common Stock, Shares Authorized	250,000,000		250,000,000
Preferred Stock, Shares Authorized	10,000,000		10,000,000
Paid-In-Kind Interest	$ 192,785	$ 0
Common Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001
Common Stock [Member]
Class of Stock [Line Items]
Paid-In-Kind Interest	$ 192,785
Accounts Payable	16,391
Debt Conversion, Original Debt, Amount	$ 341,085
Common Stock, Par or Stated Value Per Share	$ 0.0001

Preferred Stock (Details)

Preferred Stock (Details) - USD ($)		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001
Share Price (in dollars per share)		$ 2
Issuance of stock, Gross Proceeds		$ 538,327	$ 0
Balance at December 31, 2014, Par Value (in value)		334
Issuance of stock, Par Value (in value)		550,260	$ 0
Stock dividend, Par Value (in value)		0
Balance at March 31, 2015, Par Value (in value)		0
Additional Paid-in Capital [Member]
Class of Stock [Line Items]
Stock dividend, Par Value (in value)		156,048
Balance at December 31, 2014, Additional paid in Capital	[1]	6,675,118
Issuance of stock, Additional Paid in Capital	[1],[2]	740,063
Stock dividend, Additional paid in Capital	[1]	156,048
Conversion of preferred stock, Additional paid in Capital	[1]	(7,571,229)
Balance at March 31, 2015, Additional paid in Capital	[1]	$ 0
Preferred Stock [Member]
Class of Stock [Line Items]
Balance (in shares)		3,337,725
Issuance of stock	[2]	370,050
Stock dividend		78,040
Conversion of preferred stock		(3,785,815)
Balance (in shares)		0
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001
Share Price (in dollars per share)		$ 2
Issuance of stock, Gross Proceeds	[2]	$ 740,100
Stock dividend, Gross Proceeds		(156,056)
Conversion of preferred stock, Gross Proceeds		(7,259,496)
Balance at December 31, 2014, Par Value (in value)		334
Issuance of stock, Par Value (in value)	[2]	37
Stock dividend, Par Value (in value)		8
Conversion of preferred stock, Par Value (in value)		(379)
Balance at December 31, 2014, Gross Proceeds		6,675,452
Balance at June 30, 2015, Gross Proceeds		$ 0
Preferred Stock [Member] | Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001
Share Price (in dollars per share)		2
Preferred Stock [Member] | Stock Dividend [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		0.0001
Share Price (in dollars per share)		2
Preferred Stock [Member] | Issuance of stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	[2]	0.0001
Share Price (in dollars per share)	[2]	$ 2
[1]	Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
[2]	Shares issued contain an anti-dilution provision expiring upon the conversion to common stock.

Preferred Stock (Details Textua

Preferred Stock (Details Textual) - Class of Stock [Domain] - Subsequent Event Type [Domain] - $ / shares	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Share Price	2
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.375
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	200,000
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	50,000
Preferred Stock, Conversion Basis	The Preferred Stock automatically converted into shares of Common Stock determined by dividing the stated value by $0.25 per share on March 31, 2015.
Preferred Stock, Dividend Rate, Percentage	6.00%
Warrant Term	3 years

Stock Options and Stock-based55

Stock Options and Stock-based Compensation (Details) - Employee Stock Option [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding	7,019,750
Shares, Granted	882,500
Shares, Exercised	0
Shares, Cancelled or expired	(294,687)
Shares, Outstanding	7,607,563	7,019,750
Shares Exercisable	4,983,854	4,596,467
Weighted Average Exercise Price, Outstanding	$ 0.92
Weighted Average Exercise Price, Granted	0.53
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Cancelled or expired	0.55
Weighted Average Exercise Price, Outstanding	0.89	$ 0.92
Weighted Average Exercise Price, Exercisable	$ 1.08	$ 1.11
Weighted Average Remaining Contractual Life (in years), Outstanding	6 years 5 months 8 days	6 years 8 months 8 days
Weighted Average Remaining Contractual Life (in years), Exercisable	6 years 4 months 24 days	5 years 11 months 12 days

Stock Options and Stock-based56

Stock Options and Stock-based Compensation (Details 1) - Jun. 30, 2015 - $ / shares	Total
Exercise Price 0.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding (in shares)	159,000
Options Exercisable (in shares)	146,000
Exercise Price 0.53 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding (in shares)	635,000
Options Exercisable (in shares)	0
Exercise Price 0.55 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding (in shares)	3,844,063
Options Exercisable (in shares)	1,868,354
Exercise Price 0.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding (in shares)	320,000
Options Exercisable (in shares)	320,000
Exercise Price 1.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding (in shares)	310,000
Options Exercisable (in shares)	310,000
Exercise Price 1.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding (in shares)	2,124,750
Options Exercisable (in shares)	2,124,750
Exercise Price 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding (in shares)	214,750
Options Exercisable (in shares)	214,750
Exercise Price 0.50 - 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding (in shares)	7,607,563
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	6 years 5 months 8 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.89
Options Exercisable (in shares)	4,983,854
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 1.08

Stock Options and Stock-based57

Stock Options and Stock-based Compensation (Details 2) - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Nonvested, Beginning Balance	2,423,283
Shares, Granted	635,000
Shares, Forfeited	(294,687)
Shares, Vested	(139,887)
Shares, Nonvested at Ending Balance	2,623,709
Weighted Average Grant-date Fair Value, Nonvested, Beginning Balance	$ 0.258
Weighted Average Grant-date Fair Value, Granted	0.313	$ 0.206
Weighted Average Grant-date Fair Value, Forfeited	0.251
Weighted Average Grant-date Fair Value, Vested	0.386
Weighted Average Grant-date Fair Value, Nonvested, Ending Balance	$ 0.237

Stock Options and Stock-based58

Stock Options and Stock-based Compensation (Details 3) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 159,154	$ 179,049
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	137,092	163,541
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 22,062	$ 15,508

Stock Options and Stock-based59

Stock Options and Stock-based Compensation (Details 4)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free interest rate	1.67%	1.91%
Volatility factor	66.26%	69.96%
Weighted average expected life (in years)	8 years	7 years
Dividend rate	0.00%	0.00%

Stock Options and Stock-based60

Stock Options and Stock-based Compensation (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2012	Dec. 31, 2002
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value			$ 25,000
Share-based Compensation Arrangement by Share-based Payment Award Estimated Fair Value of Stock Price (in dollars per share)	$ 0.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in dollars)	$ 159,154	$ 179,049
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.313	$ 0.206
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Expected Term	2 years 4 months 24 days
Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested And Expected To Vest Fair Value	$ 533,923
Equity Incentive Plan 2002 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				4,150,000	450,000
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	5,000,000

Stock Warrants (Details)

Stock Warrants (Details) - Warrant [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Shares, Outstanding at December 31, 2014	53,112,193
Shares, Granted	11,978,223
Shares, Exercised	0
Shares, Cancelled or expired	(751,667)
Shares, Outstanding at June 30, 2015	64,338,749	53,112,193
Weighted Average Exercise Price, Outstanding at December, 2014	$ 0.98
Weighted Average Exercise Price, Granted	0.38
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Cancelled or expired	2
Weighted Average Exercise Price, Outstanding at June 30, 2015	$ 0.86	$ 0.98
Weighted Average Remaining Contractual Life (in years), Outstanding	2 years 11 months 1 day	3 years 3 months 7 days
Weighted Average Remaining Contractual Life (in years), Granted	3 years 4 months 2 days

Stock Warrants (Details 1)

Stock Warrants (Details 1) - Class of Stock [Domain] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.375
Exercise Price 0.38
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.38
Warrants Outstanding (in shares)	14,831,098
Exercise Price 0.50
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.50
Warrants Outstanding (in shares)	1,100,523
Exercise Price 0.64
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.64
Warrants Outstanding (in shares)	11,065,144
Exercise Price 0.80
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.80
Warrants Outstanding (in shares)	1,415,000
Exercise Price 1.10
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 1.10
Warrants Outstanding (in shares)	19,054,350
Exercise Price 1.12
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 1.12
Warrants Outstanding (in shares)	263,750
Exercise Price 2.00
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2
Warrants Outstanding (in shares)	5,984,175
Exercise Price 2.20
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.20
Warrants Outstanding (in shares)	98,320
Exercise Price 2.25
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.25
Warrants Outstanding (in shares)	1,296,389
Exercise Price 0.33
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.33
Warrants Outstanding (in shares)	7,500,000
Exercise Price 0.45
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.45
Warrants Outstanding (in shares)	1,730,000
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	64,338,749
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	2 years 11 months 1 day	3 years 3 months 7 days
Warrant Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.86	$ 0.98
Warrant [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	2.25
Warrant [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.33

Stock Warrants (Details Textual

Stock Warrants (Details Textual) - Related Party [Domain] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Class of Warrant or Right [Line Items]
Interest Expense, Other			$ 117,041	$ 125,645
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.375		$ 0.375
Cost of Services				49,921
Induced Conversion of Convertible Debt Expense	$ 0	$ 0	$ 60,419	$ 0
Adjustments To Additional Paid In Capital Issuance Of Warrant For Placement Agent			$ 170,418
Warrants Earned During the Period			4,654,145
Minimum [Member] | Winter Offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.64		$ 0.64
Maximum [Member] | Winter Offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75		$ 0.75
Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	64,338,749		64,338,749
Adjustments To Additional Paid In Capital Issuance Of Warrant For Placement Agent			$ 0
Common Stock [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right Term of Warrants or Rights			$ 0.325
Common Stock [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right Term of Warrants or Rights			$ 2.25
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	64,338,749		64,338,749
Cost of Services			$ 98,683
Warrant [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.33		$ 0.33
Warrant [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.25		$ 2.25

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Operating Loss Carryforwards, Expiration Dates	expire beginning 2021 for both federal and state purposes
Income Tax Examination, Likelihood of Unfavorable Settlement	greater than 50% likelihood
Operating Loss Carryforwards	$ 63,500,000	$ 59,800,000

Lease Commitments (Details)

Lease Commitments (Details)	Jun. 30, 2015USD ($)
Lease Commitments [Line Items]
2015 (payment in arrears)	$ 27,939
2015 (April - December)	128,260
2,016	172,428
2,017	46,707
2,018	4,800
2,019	$ 4,000

Lease Commitments (Details Text

Lease Commitments (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Lease Commitments [Line Items]
Description of Lessor Leasing Arrangements, Operating Leases			The Company leases its facilities under operating leases beginning a) February 2005 and extended through September 2015 and b) April 2012 through March 2017.
Operating Leases, Rent Expense (in dollars)	$ 65,636	$ 94,220	$ 142,993	$ 189,048
Lessee Leasing Arrangements, Operating Leases, Term of Contract			5 years

Retirement Plan (Details Textua

Retirement Plan (Details Textual)	6 Months Ended
	Jun. 30, 2015
Retirement Plan [Line Items]
Description of Postemployment Benefits	The Company provides a 401(k) Profit Sharing Plan (401(k) Plan) for elective deferrals whereby participants can defer up to 85% of their wages not to exceed a maximum dollar amount determined by the Federal Government each year.

Commitments and Contingencies (

Commitments and Contingencies (Details Textual)	3 Months Ended	6 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2015EUR (€)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2014EUR (€)
Loss Contingencies [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident (in dollars)		$ 5,000,000
Accrued warranties	$ 50,000	50,000			$ 50,000
Payments To Acquire Machinery and Equipment		44,132		$ 119,983
Omics2image [Member]
Loss Contingencies [Line Items]
Payments to Acquire Projects		46,600	€ 40,000
George Washington University (GWU) [Member]
Loss Contingencies [Line Items]
Royalty Expenses (in dollars)	9,445	20,211
License Costs		25,000
Minimum License Diligence Resources Year Two		12,500
Minimum License Diligence Resources After Year Two		20,000
License and Maintenance Revenue		$ 30,000
Royalties Percentage on Net Sales of Licensed Products		7.00%	7.00%
Royalties Percentage on Combination Products for Combined Cumulative Net Sales		5.00%	5.00%
Sales Revenue, Services, Net		$ 50,000,000
Reduce Royalties Percentage After Net Sales of Licensed Products		6.00%	6.00%
Reduce Royalties Percentage on Combination Products for Combined Cumulative After Net Sales		4.00%	4.00%
Minimum Royalties Year One	1,500	$ 1,500
Minimum Royalties Year Two	2,500	2,500
Minimum Royalties Year Three	3,500	3,500
Minimum Royalties Year After Three Year	6,000	6,000
Accrued Royalties, Current	24,000	24,000			29,300
Accounts Payable, Current	33,433	33,433
Dynamic Manufacturing LLC [Member]
Loss Contingencies [Line Items]
Accounts Payable and Accrued Liabilities, Current (in dollars)	0	0
Commitments Outstanding	320,238	320,238
Payments To Acquire Machinery and Equipment	53,063
Bridger Photonics [Member]
Loss Contingencies [Line Items]
Accounts Payable and Accrued Liabilities, Current (in dollars)	$ 0	$ 0
COAST Project [Member]
Loss Contingencies [Line Items]
Commitments Outstanding					$ 76,000	€ 60,000

Contingent Acquisition (Details

Contingent Acquisition (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Mar. 31, 2015
Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Convertible Preferred Stock, Terms of Conversion	(a) the volume weighted average price of the Companys common stock for any 20 consecutive trading days shall equal or exceed 150% of the conversion price then in effect; or (b) the Company shall consummate an underwritten public offering of not less than $15,000,000 of its shares of common stock
Vivo Pharm Pty. Ltd [Member]
Business Acquisition [Line Items]
Purchase Price For Shares Purchased		$ 12,063,084
Payable By Way of Deposit Prior To The Closing Of The Acquisition		100,000
Payable In Cash At The Closing Of The Acquisition		$ 5,690,280
Business Acquisition, Percentage of Voting Interests Acquired		100.00%
Required Additional Financing For Acquisition	$ 10,000,000
Convertible Preferred Stock, Terms of Conversion	(a) the same price per share at which the Company sells shares of its Common Stock, or the highest conversion price or exercise price per share of any convertible securities, in either case, as issued in connection with the Required Financing contemplated by the Purchase Agreement, or (b) forty ($0.40) cents.
Vivo Pharm Pty. Ltd [Member] | Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Payable In The Form Of Share Capital		$ 6,272,804
Payable In The Form Of Shares		627,280.4
Preferred Stock, Liquidation Preference Per Share		$ 10

Evaluation of Subsequent Even70

Evaluation of Subsequent Events (Details Textual) - Sale of Stock, Name of Transaction [Domain] - Range [Domain] - Long-term Debt, Type [Domain] - Related Party [Domain] - Class of Stock [Domain] - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Subsequent Event [Line Items]
Proceeds from Related Party Debt	$ 1,048,000	$ 2,025,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.375
Common Stock, Shares, Issued	114,900,808		66,588,600
Warrants Expiration Terms	5 years
Share Price	$ 2
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Related Party Debt	$ 135,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.50
Due from Officers or Stockholders, Current	$ 1,353,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized	150,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 0.48
Subsequent Event [Member] | Director [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued For Services	90,910
Share Price	$ 0.33
Subsequent Event [Member] | Director [Member] | Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Proceeds from Convertible Debt	$ 200,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Instrument, Convertible, Conversion Price	$ 0.33
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued	100,000